迄今,美国食品及药物管理局(Food and Drug Administration, FDA)已批准7款PD-1/PD-L1抑制剂用于85个适应证;中国国家药品监督管理局(National Medical Products Administration, NMPA)批准11款PD-1/PD-L1抑制剂用于44个适应证,并得到国家医保局的大力...
PD-1/PD-L1抑制剂(新通药物): 一种PD-1抑制剂、PDL1抑制剂药物,由Xi'an Xintong Pharmaceutical Research Co., Ltd. (西安新通药物研究股份有限公司)公司最早进行研发,目前全球最高研发状态为临床前,作用机制: PD-1抑制剂(细胞程序性死亡-1抑制剂),PDL1抑制剂(程序性死亡
根据肿瘤细胞PD-L1 表达水平以1%和 5%为临界值分析显示,122 例 PD-L1≥1%的患者ORR 为 23.8%,而 143 例 PD-L1<1%的患者 ORR 为16.1%;81 例 PD-L1≥5%的患者ORR为28.4%,184例PD-L1<5%的患者ORR为15.8%。PD-L1≥1%...
This review summarized the combination therapy based on PD-1/PD-L1 inhibitors in TNBC patients, in order to provide reference for clinical treatment of TNBC patients. KEYWORDS: Triple-negative breast cancer;Immunotherapy;Programmed cell death protein-1 inhibitor;Programmed cell death-ligand 1 inhibitor...
This review summarized the combination therapy based on PD-1/PD-L1 inhibitors in TNBC patients, in order to provide reference for clinical treatment of TNBC patients. KEYWORDS: Triple-negative breast cancer;Immunotherapy;Programmed cell death protein-1 inhibitor;Programmed cell death-ligand 1 inhibitor...
但要指出的是,虽然几乎所有数字都在继续增长,但患者招募出现了显著下降:尽管PD-1/PD-L1联合试验仍然能比其他癌症试验更快地招募患者,但招募在四年内减缓了70%。这可能是因为最近多个PD-1/PD-L1治疗方案获批,导致护理标准出现快速变化,以及同类试验对相对较小的受试患者群的竞争结果。这表明需要扩大可以参与药物试...
这些药物针对417个靶点,榜单前列的靶点是CD19,PD-1,PD-L1,HER2和STAT3等。 免疫检查点抑制剂通过阻断PD-1等免疫检查点与配体结合,来消除对T细胞活性的抑制,从而提高T细胞杀伤肿瘤的能力。这类疗法问世以来已被用于治疗多种癌症,包括黑色素瘤、非小细胞肺癌、头颈癌、宫颈癌等等。今年,针对PD-1/PD-L1的药物正在...
In the IMbrave150 clinical trial, the immune combination regimen of the PD-L1 inhibitor Atezolizumab plus the VEGF inhibitor Bevacizumab(AT) demonstrated significant efficacy in unresectable HCC, and became the new standard of care for first line systemic therapy.11 In recent years...
The observation group was given radiotherapy combined with PD1 inhibitor and TKI treatment, and the control group was given TKI monotherapy. The baseline data, treatment effect, progressionfree survival, and treatmentrelated adverse reactions of patients in th...
PD-1 Antibody (Tislelizumab) Combined With VEGFR 1/2/3 Inhibitor (Fruquintinib) for ARID1A-mutated Metastatic pMMR/MSS Colorectal Cancer: an Open-label, Multi-center, Phase II Clinical Trial This is an open-label phase II study, with the aim of investigating the efficacy and safety of...